Tablet and capsule lines processing praziquantel for companion animal cestode control are built around a micronised active pharmaceutical ingredient with low aqueous solubility and a dose-per-unit mass that makes content uniformity the primary manufacturing risk. Wet granulation begins by pre-blending praziquantel with lactose monohydrate, maize starch, and polyvinylpyrrolidone in a high-shear granulator with bowl volumes of 10–150 L, impeller speeds of 300–800 rpm, and chopper speeds of 1500–3000 rpm. A purified water plus povidone binder solution is added to reach granulate moisture of 8–12% w/w. The wet mass is discharged through a 2.0 mm screen and dried in a fluid-bed dryer with inlet air at 45–55°C until loss-on-drying reaches 1.5–2.5%. Dried granulate is milled through a 0.8–1.2 mm screen, blended with croscarmellose sodium and magnesium stearate, and compressed on a rotary tablet press at 25–45 rpm using pre-compression force of 4–8 kN and main compression force of 10–25 kN. Tablet hardness is controlled between 60–120 N, and friability is kept below 1.0% under USP <1216>. For capsule filling, the granulate is brought to a bulk density of 0.45–0.65 g/mL and filled into size 2–4 hard gelatin capsules on automatic dosator equipment. Compliance is anchored to 21 CFR 520.1870 for praziquantel tablets, compendial API assay limits of 98.0–102.0%, uniformity of dosage units per USP <905> or Ph. Eur. 2.9.5, residual solvents per ICH Q3C, and elemental impurities per ICH Q3D. Formulation addition ratio for praziquantel in finished tablet cores typically occupies 5–35% w/w in multi-component anthelmintic products; commercially labelled strengths include 23 mg, 34 mg, and 50 mg praziquantel per tablet in combination with pyrantel embonate, febantel, or milbemycin oxime, with a target dose rate of 5 mg/kg body weight. Terminal product types are compressed tablets and hard capsules for dogs and cats, with light-protective blister packaging used where tropical export conditions create photostability stress. Process incompatibility arises with alkaline granulating fluids: praziquantel remains stable in neutral or weakly acidic granulate but can undergo hydrolysis under prolonged high-moisture basic conditions, so ammonia-based buffers are avoided and drying is completed below 55°C.

Why Does a 56.8 mg/mL Injectable Solution Require a Non-Aqueous Vehicle?

Parenteral praziquantel for companion animals is formulated as a sterile solution at 56.8 mg/mL because aqueous isotonic solvents cannot hold the active pharmaceutical ingredient at pharmacological concentration; the aqueous solubility of praziquantel is commonly cited as below 1 mg/mL at 25°C, requiring a co-solvent system based on benzyl alcohol, propylene glycol, or glycerol formal. The formulation addition ratio is 5.68% w/v praziquantel in the finished solution, with preservative excipients maintained within compendial antimicrobial effectiveness testing limits under USP <51> and Ph. Eur. 5.1.3. Production on an injectable filling line begins with solvent pre-heating to 35–40°C, dissolution of the active under high-torque agitation, cooling to 20–25°C, and sequential filtration through 0.45 μm and 0.22 μm sterilising membrane filters. Filling occurs under Grade A laminar airflow with aseptic control per USP <71> and Ph. Eur. 2.6.1, using amber Type I borosilicate vials of 10–100 mL and elastomeric stoppers that have passed compendial extractables testing. The terminal product is a clear, sterile injectable solution for subcutaneous or intramuscular use in dogs and cats. A critical processing boundary is moisture ingress: because praziquantel precipitates when residual water exceeds the co-solvent capacity, holding tanks and silicone hoses must be dried after cleaning and steam sterilisation, and the formulation is blanketed with nitrogen to limit condensation. Batch-to-batch variance in active pharmaceutical ingredient particle size does not materially affect dissolution kinetics in this solvent-based process, but residual water in the incoming active above 0.5% w/w can destabilise the vehicle and reduce final clarity, so loss-on-drying is tested before batching.

Equine paste and gel filling lines differ from tablet compression in that the primary material challenge is not granule flow but shear-induced structural change and particle settling in a non-Newtonian vehicle. Praziquantel for equine cestode control is blended with ivermectin or moxidectin in an oleaginous base, with praziquantel addition ratios between 7.75% w/w and 14.03% w/w in finished paste formulations and ivermectin present at 1.55–1.87% w/w; equine labels are calibrated to deliver ivermectin at 0.2 mg/kg and praziquantel in the 1–2 mg/kg range from multi-dose syringes marked in 50–100 kg bodyweight increments. Manufacturing uses a heated high-shear jacketed kettle for wax and oil phases, followed by addition of micronised praziquantel through a vacuum induction mixer to limit dust generation. The blend is passed through a triple roller mill at gap settings of 50–150 μm to break agglomerates, cooled to 25–30°C, and filled on airless piston fillers into high-density polyethylene or aluminium-barrier laminate syringes. Compliance is anchored to VICH GL3 stability matrices, Ph. Eur. 2.9.40 for semi-solid uniformity, and residual solvent limits under ICH Q3C; imported products require approval under 21 CFR 520. Finished product types are oral paste syringes, ready-to-use oral gels, and barrier-packed multi-dose paste tubes for horses and ponies. Process limits include thixotropic behaviour of the vehicle: filling temperature must remain within ±3°C of the validated set point because viscosity shifts above 35°C cause fill weight variation, while temperatures below 20°C produce air entrapment and visible bubble defects. Oxidation-sensitive components in combination formulas require nitrogen blanketing and the use of butylated hydroxytoluene or tocopherol within compendial antioxidant limits.

Feed Premix and Aqueous Dispersions for Aquaculture Systems

Praziquantel use in fish is divided between ornamental immersion treatment and medicated feed premix for intestinal cestodes, with regulatory status sharply split between non-food species and food-fish production. In ornamental fish, bath concentrations of 2 mg/L for 24 h or 10 mg/L for 3 h are prepared by first dissolving praziquantel in ethanol or dimethylsulfoxide at a stock concentration of 5–10% w/v before slow dilution into aerated holding tanks; direct addition of powder to water is unsuitable because the low aqueous solubility leaves undissolved particles that settle and produce gill irritation. For feed premixes, praziquantel is added at 0.25–0.5% w/w of final pellet mash, with a target intake of 5 mg/kg fish body weight over 3–5 days. Production of the premix follows geometric dilution in a ribbon blender with a coefficient of variation below 5%, followed by wet extrusion at barrel temperatures of 90–110°C and die pressures of 15–30 bar; post-extrusion drying at 60–70°C reduces final moisture to 8–10%. Compliance is governed primarily by national aquaculture drug licensing; in the United States food-fish use is not approved, and any extra-label use must satisfy 21 CFR 530.41 restrictions and residue monitoring, while ornamental use falls outside food-safety maximum residue limit obligations. End products include soluble concentrate sachets for immersion baths, medicated sinking pellets, and pressure-pelleted feed granules. The major process incompatibility is high-temperature extrusion above 110°C combined with acidic mash: praziquantel recovery can decline under low-pH, high-heat conditions, so post-extrusion assay loss must be monitored and overage validated by stability studies; published data for exact extrusion recovery in praziquantel aquatic feeds is limited.

When Ruminant Tapeworm Control Moves Through Oral Drenches and Feed-Grade Premixes

Ruminant tapeworm infections caused by Moniezia spp. require a formulation strategy that matches the labour constraints of extensive grazing systems, typically a ready-to-use oral drench or a milled feed premix that can be blended into a total mixed ration. Praziquantel is formulated into oral drenches at 2.5–5.0% w/v, with a dose rate of 3.75–5 mg/kg body weight, often in combination with levamisole or a macrocyclic lactone; the addition ratio in dry feed premixes is 1–2% w/w praziquantel in a lactose or calcium carbonate carrier, diluted to 0.1–0.25% w/w in final feed. Liquid drench manufacturing uses ambient-temperature high-shear mixing with surfactant wetting agents, followed by pH adjustment to 4.0–5.5 with citric acid to maintain chemical stability, and filtration through 50–100 μm screens before filling into high-density polyethylene dosing bottles. Dry premix production follows stepwise blending in a contra-rotating ribbon mixer for 15–20 min, with post-blend assay sampling from 10–20 points to verify homogeneity using ≤5% RSD; the premix is then incorporated into pelleted feed at 70–80°C conditioning temperature, which is below the degradation threshold for praziquantel in neutral pH rations. Compliance in the European Union requires marketing authorisation under Regulation (EU) 2019/6, with maximum residue limits referenced through Regulation (EC) No 470/2009; in the United States, use in ruminants requires an approved product or veterinary prescription under extra-label provisions of 21 CFR 530. Terminal product types include oral drench suspensions, in-feed granules, and custom-mix premises for cattle, sheep, and goats. The critical incompatibility is with high-moisture silage rations that lower rumen pH: praziquantel release from feed particles is not pH-dependent, but acidic pellet binders can reduce recovery during stability testing, and calcium carbonate carriers should be avoided in acid-preserved grain because effervescent reactions physically disrupt pellet integrity.

Zoo and exotic animal clinics require flexible oral liquid preparations because solid dosage units cannot be safely adjusted for small animals with body masses under 500 g. Praziquantel is compounded into oral suspensions at 1–10 mg/mL using a levitating wetting agent such as polysorbate 80 and a suspending vehicle containing carboxymethylcellulose sodium; addition ratio in the compounded preparation is calculated from the veterinary prescription at 5–10 mg/kg body weight for reptiles, birds, and small mammals. The preparation process uses a high-shear homogeniser at 3000–6000 rpm for 5–10 min, followed by pH adjustment to 4.5–5.5 and packaging in amber polyethylene terephthalate bottles with child-resistant closures. Quality control follows USP <795> for nonsterile compounding, including beyond-use dating not exceeding 35 days under refrigerated storage; where a licensed product is used off-label, 21 CFR 530 establishes veterinary oversight and residue implications. End products are oral solutions and suspensions for chelonians, psittacine birds, and ferrets, with dose volumes delivered by calibrated oral syringe. The main process boundary is microbial preservation: because the preparation is nonsterile and contains a low-solubility active in aqueous suspension, the preservative system must pass antimicrobial effectiveness testing under USP <51>, and steam sterilisation at 121°C is avoided because it introduces re-dispersion and packaging integrity problems rather than a validated terminal sterilisation route.